{"protocolSection":{"identificationModule":{"nctId":"NCT00684307","orgStudyIdInfo":{"id":"D1250C00008"},"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation","officialTitle":"A Controlled, Randomized, Parallel, Multicentre Study to Assess Safety and Tolerability of the Oral Direct Thrombin Inhibitor AZD0837, Given as an Extended-release Formulation, in the Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation"},"statusModule":{"statusVerifiedDate":"2012-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-02"},"primaryCompletionDateStruct":{"date":"2008-06","type":"ACTUAL"},"completionDateStruct":{"date":"2008-06","type":"ACTUAL"},"studyFirstSubmitDate":"2008-05-22","studyFirstSubmitQcDate":"2008-05-23","studyFirstPostDateStruct":{"date":"2008-05-26","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-08-17","resultsFirstSubmitQcDate":"2011-08-17","resultsFirstPostDateStruct":{"date":"2011-09-22","type":"ESTIMATED"},"lastUpdateSubmitDate":"2012-03-20","lastUpdatePostDateStruct":{"date":"2012-03-23","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The main purpose of this study is to provide dose-guiding information by assessing the safety and tolerability of 4 different dosing regimens of an extended-release (ER) formulation of AZD0837 compared with well-controlled, dose-adjusted Vitamin-K antagonists (VKA) (aiming for an international normalized ratio (INR) 2.0 to 3.0) in patients with non-valvular atrial fibrillation (AF) with one or more additional risk factors for stroke."},"conditionsModule":{"conditions":["Nonvalvular Atrial Fibrillation"],"keywords":["Anticoagulant Treatment","Risk Factors For Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":1084,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","description":"AZD0837 450 mg","interventionNames":["Drug: AZD0837"]},{"label":"2","type":"EXPERIMENTAL","description":"AZD0837 200 mg","interventionNames":["Drug: AZD0837"]},{"label":"3","type":"EXPERIMENTAL","description":"AZD0837 300 mg","interventionNames":["Drug: AZD0837"]},{"label":"4","type":"EXPERIMENTAL","description":"AZD0837 150 mg","interventionNames":["Drug: AZD0837"]},{"label":"5","type":"ACTIVE_COMPARATOR","description":"Vitamin-K antagonist at INR 2-3","interventionNames":["Drug: Vitamin-K antagonist at INR 2-3"]}],"interventions":[{"type":"DRUG","name":"AZD0837","description":"ER tablet, PO, once daily for a period of 3-9 months.","armGroupLabels":["1","3","4"]},{"type":"DRUG","name":"Vitamin-K antagonist at INR 2-3","description":"Tablet, PO for a period of 3-9 months.","armGroupLabels":["5"],"otherNames":["Warfarin"]},{"type":"DRUG","name":"AZD0837","description":"ER tablet, PO, twice daily for a period of 3-9 months","armGroupLabels":["2"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Bleeding Events","description":"Number of patients with a bleeding event while on study drug. Patients with multiple events are counted once","timeFrame":"36 weeks according to protocol. For patients who discontinued treatment the time frame was <36 weeks. Mean number of weeks was 21 weeks (baseline to end of treatment visit)"},{"measure":"Creatinine","description":"Change in Creatinine values from baseline to week 12 visit for patients while on study drug (week 12 visit-baseline)","timeFrame":"12 weeks according to protocol.(baseline to week 12 visit)"},{"measure":"Alanine Aminotransferase (ALAT)","description":"Number of patients while on study drug with ALAT\\>=3 times upper limit of normal.l","timeFrame":"36 weeks according to protocol. For patients who discontinued treatment the time frame was <36 weeks. Mean number of weeks was 21 weeks (baseline to end of treatment visit)"},{"measure":"Bilirubin","description":"Number of patients while on study drug with Bilirubin\\>=2 times upper limit of normal","timeFrame":"36 weeks according to protocol. For patients who discontinued treatment the time frame was <36 weeks. Mean number of weeks was 21 weeks (baseline to end of treatment visit)"}],"secondaryOutcomes":[{"measure":"D-Dimer","description":"Change in D-Dimer values from enrolment to week 12 visit for VKA na誰ve patients while on study drug (week 12 visit-enrolment)","timeFrame":"14 weeks according to protocol.(enrolment to week 12 visit)"},{"measure":"Activated Partial Thromboplastin Time (APTT)","description":"Change in Activated partial thromboplastin time (APTT) from baseline to week 12 visit for VKA na誰ve patients while on study drug (week 12 visit-baseline)","timeFrame":"12 weeks according to protocol.(baseline to week 12 visit)"},{"measure":"Ecarin Clotting Time (ECT)","description":"Change in Ecarin clotting time (ECT) from baseline to week 12 visit for patients while on study drug (week 12 visit-baseline)","timeFrame":"12 weeks according to protocol.(baseline to week 12 visit)"},{"measure":"Plasma Concentration of AZD0837 (Prodrug)","description":"Assessment made on the week 12 visit","timeFrame":"12 weeks after baseline according to protocol"},{"measure":"Plasma Concentration of AR-H067637XX (Active Metabolite)","description":"Assessment made on the week 12 visit","timeFrame":"12 weeks after baseline according to protocol"},{"measure":"Oral Clearance (CL/F) of AR-H067637XX (Active Metabolite) for C3435T Genotype TT","description":"Oral clearance of AR-H067637XX in subgroup of patients with genotype TT for gene polymorphism ABCB1 C3435T","timeFrame":"36 weeks according to protocol"},{"measure":"Oral Clearance (CL/F) of AR-H067637XX (Active Metabolite) for C3435T Genotype TC","description":"Oral clearance of AR-H067637XX in subgroup of patients with genotype TC for gene polymorphism ABCB1 C3435T","timeFrame":"36 weeks according to protocol"},{"measure":"Oral Clearance (CL/F) of AR-H067637XX (Active Metabolite) for C3435T Genotype CC","description":"Oral clearance of AR-H067637XX in subgroup of patients with genotype CC for gene polymorphism ABCB1 C3435T","timeFrame":"36 weeks according to protocol"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Nonvalvular AF (NVAF) verified by at least two ECGs in the last year separated by at least one week.\n* Previous cerebral ischemic attack (stroke or TIA, \\>30 days prior to randomization)\n* Previous systemic embolism.\n* Symptomatic congestive heart failure (CHF)\n* Impaired left ventricular systolic function\n* Diabetes mellitus\n* Hypertension requiring anti-hypertensive treatment.\n\nExclusion Criteria:\n\n* AF secondary to reversible disorders, eg hyperthyroidism, drugs and pulmonary embolism\n* Known contraindication to VKA treatment\n* Presence of a valvular heart disease, mechanical heart valves, active endocarditis, left ventricular aneurysm or thrombus, atrial myxoma or any condition other than AF requiring chronic anticoagulation treatment\n* Conditions associated with increased risk of major bleeding for example: history of intracranial bleeding, history of bleeding gastrointestinal disorder or major surgical procedure or trauma two weeks prior to randomization","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Gregory Y Lip, Prof","affiliation":"University Department of Medicine, City Hospital, Birmingham, B18 7QH, England, UK","role":"PRINCIPAL_INVESTIGATOR"}]},"referencesModule":{"references":[{"pmid":"19690349","type":"DERIVED","citation":"Lip GY, Rasmussen LH, Olsson SB, Jensen EC, Persson AL, Eriksson U, Wahlander KF; Steering Committee. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J. 2009 Dec;30(23):2897-907. doi: 10.1093/eurheartj/ehp318. Epub 2009 Aug 18."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Participants were enrolled in the study up to two weeks before randomisation and treatment assignment. Participants that were already treated with Vitamin K Antagonists (VKA) at the time of enrollment had their dose adjusted to achive INR \\<2.0 at the time of randomisation. If this was not achieved the participant was discontinued from the study.","recruitmentDetails":"The study population included male and female participants \\>18 years of age with chronic non-valvular Atrial Fibrillation. The participants were recruited during the time period from 20 February 2007 to 5 June 2008 at medical clinics in Europe.","groups":[{"id":"FG000","title":"150 mg od","description":"AZD0837 150 mg od"},{"id":"FG001","title":"300 mg od","description":"AZD0837 300 mg od"},{"id":"FG002","title":"450 mg od","description":"AZD0837 450 mg od"},{"id":"FG003","title":"200 mg bd","description":"AZD0837 200 mg bd"},{"id":"FG004","title":"VKA INR 2-3"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Patients who received treatment","numSubjects":"164"},{"groupId":"FG001","numSubjects":"151"},{"groupId":"FG002","numSubjects":"156"},{"groupId":"FG003","numSubjects":"160"},{"groupId":"FG004","numSubjects":"318"}]},{"type":"On Treatment Period Started","achievements":[{"groupId":"FG000","numSubjects":"164"},{"groupId":"FG001","numSubjects":"151"},{"groupId":"FG002","numSubjects":"156"},{"groupId":"FG003","numSubjects":"160"},{"groupId":"FG004","numSubjects":"318"}]},{"type":"On Treatment Period Completed","achievements":[{"groupId":"FG000","comment":"Patients who completed treatment","numSubjects":"140"},{"groupId":"FG001","numSubjects":"129"},{"groupId":"FG002","numSubjects":"128"},{"groupId":"FG003","numSubjects":"128"},{"groupId":"FG004","numSubjects":"293"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"140"},{"groupId":"FG001","numSubjects":"129"},{"groupId":"FG002","numSubjects":"128"},{"groupId":"FG003","numSubjects":"128"},{"groupId":"FG004","numSubjects":"293"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"22"},{"groupId":"FG002","numSubjects":"28"},{"groupId":"FG003","numSubjects":"32"},{"groupId":"FG004","numSubjects":"25"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"15"},{"groupId":"FG003","numSubjects":"16"},{"groupId":"FG004","numSubjects":"8"}]},{"type":"Development of increasing Liver Function","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Fullfillment of exclusion criteria","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"1"}]},{"type":"Incorrect enrolment or randomization","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}]},{"type":"Interupted IP for more than 7 days","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"3"}]},{"type":"Severe non compliance to protocol","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"2"}]},{"type":"Participant not willing to continue","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"8"}]},{"type":"Criteria from the CSR","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"3"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"150 mg od","description":"AZD0837 150 mg od"},{"id":"BG001","title":"300 mg od","description":"AZD0837 300 mg od"},{"id":"BG002","title":"450 mg od","description":"AZD0837 450 mg od"},{"id":"BG003","title":"200 mg bd","description":"AZD0837 200 mg bd"},{"id":"BG004","title":"VKA INR 2-3"},{"id":"BG005","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"164"},{"groupId":"BG001","value":"151"},{"groupId":"BG002","value":"156"},{"groupId":"BG003","value":"160"},{"groupId":"BG004","value":"318"},{"groupId":"BG005","value":"949"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9.0","spread":"69.9"},{"groupId":"BG001","value":"9.0","spread":"69.8"},{"groupId":"BG002","value":"9.4","spread":"69.3"},{"groupId":"BG003","value":"9.4","spread":"67.8"},{"groupId":"BG004","value":"9.1","spread":"68.3"},{"groupId":"BG005","value":"9.18","spread":"69.02"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"49"},{"groupId":"BG003","value":"53"},{"groupId":"BG004","value":"103"},{"groupId":"BG005","value":"299"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"117"},{"groupId":"BG001","value":"104"},{"groupId":"BG002","value":"107"},{"groupId":"BG003","value":"107"},{"groupId":"BG004","value":"215"},{"groupId":"BG005","value":"650"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Bleeding Events","description":"Number of patients with a bleeding event while on study drug. Patients with multiple events are counted once","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"36 weeks according to protocol. For patients who discontinued treatment the time frame was <36 weeks. Mean number of weeks was 21 weeks (baseline to end of treatment visit)","groups":[{"id":"OG000","title":"150 mg od","description":"AZD0837 150 mg od"},{"id":"OG001","title":"300 mg od","description":"AZD0837 300 mg od"},{"id":"OG002","title":"450 mg od","description":"AZD0837 450 mg od"},{"id":"OG003","title":"200 mg bd","description":"AZD0837 200 mg bd"},{"id":"OG004","title":"VKA INR 2-3"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"151"},{"groupId":"OG002","value":"156"},{"groupId":"OG003","value":"160"},{"groupId":"OG004","value":"318"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"46"}]}]}]},{"type":"PRIMARY","title":"Creatinine","description":"Change in Creatinine values from baseline to week 12 visit for patients while on study drug (week 12 visit-baseline)","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"umol/L","timeFrame":"12 weeks according to protocol.(baseline to week 12 visit)","groups":[{"id":"OG000","title":"150 mg od","description":"AZD0837 150 mg od"},{"id":"OG001","title":"300 mg od","description":"AZD0837 300 mg od"},{"id":"OG002","title":"450 mg od","description":"AZD0837 450 mg od"},{"id":"OG003","title":"200 mg bd","description":"AZD0837 200 mg bd"},{"id":"OG004","title":"VKA INR 2-3"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"132"},{"groupId":"OG002","value":"133"},{"groupId":"OG003","value":"134"},{"groupId":"OG004","value":"298"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.95","spread":"11.18"},{"groupId":"OG001","value":"4.81","spread":"12.74"},{"groupId":"OG002","value":"7.56","spread":"14.95"},{"groupId":"OG003","value":"9.22","spread":"11.24"},{"groupId":"OG004","value":"0.43","spread":"11.79"}]}]}]},{"type":"PRIMARY","title":"Alanine Aminotransferase (ALAT)","description":"Number of patients while on study drug with ALAT\\>=3 times upper limit of normal.l","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"36 weeks according to protocol. For patients who discontinued treatment the time frame was <36 weeks. Mean number of weeks was 21 weeks (baseline to end of treatment visit)","groups":[{"id":"OG000","title":"150 mg od","description":"AZD0837 150 mg od"},{"id":"OG001","title":"300 mg od","description":"AZD0837 300 mg od"},{"id":"OG002","title":"450 mg od","description":"AZD0837 450 mg od"},{"id":"OG003","title":"200 mg bd","description":"AZD0837 200 mg bd"},{"id":"OG004","title":"VKA INR 2-3"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"147"},{"groupId":"OG002","value":"150"},{"groupId":"OG003","value":"152"},{"groupId":"OG004","value":"315"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"5"}]}]}]},{"type":"PRIMARY","title":"Bilirubin","description":"Number of patients while on study drug with Bilirubin\\>=2 times upper limit of normal","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"36 weeks according to protocol. For patients who discontinued treatment the time frame was <36 weeks. Mean number of weeks was 21 weeks (baseline to end of treatment visit)","groups":[{"id":"OG000","title":"150 mg od","description":"AZD0837 150 mg od"},{"id":"OG001","title":"300 mg od","description":"AZD0837 300 mg od"},{"id":"OG002","title":"450 mg od","description":"AZD0837 450 mg od"},{"id":"OG003","title":"200 mg bd","description":"AZD0837 200 mg bd"},{"id":"OG004","title":"VKA INR 2-3"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"147"},{"groupId":"OG002","value":"150"},{"groupId":"OG003","value":"152"},{"groupId":"OG004","value":"315"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"}]}]}]},{"type":"SECONDARY","title":"D-Dimer","description":"Change in D-Dimer values from enrolment to week 12 visit for VKA na誰ve patients while on study drug (week 12 visit-enrolment)","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"ng/mL","timeFrame":"14 weeks according to protocol.(enrolment to week 12 visit)","groups":[{"id":"OG000","title":"150 mg od","description":"AZD0837 150 mg od"},{"id":"OG001","title":"300 mg od","description":"AZD0837 300 mg od"},{"id":"OG002","title":"450 mg od","description":"AZD0837 450 mg od"},{"id":"OG003","title":"200 mg bd","description":"AZD0837 200 mg bd"},{"id":"OG004","title":"VKA INR 2-3"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"43"},{"groupId":"OG004","value":"87"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.4","lowerLimit":"-382","upperLimit":"170"},{"groupId":"OG001","value":"-76.9","lowerLimit":"-613","upperLimit":"29"},{"groupId":"OG002","value":"-45.2","lowerLimit":"-1817","upperLimit":"230"},{"groupId":"OG003","value":"-68.0","lowerLimit":"-1313","upperLimit":"69"},{"groupId":"OG004","value":"-50.3","lowerLimit":"-3955","upperLimit":"516"}]}]}]},{"type":"SECONDARY","title":"Activated Partial Thromboplastin Time (APTT)","description":"Change in Activated partial thromboplastin time (APTT) from baseline to week 12 visit for VKA na誰ve patients while on study drug (week 12 visit-baseline)","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"sec","timeFrame":"12 weeks according to protocol.(baseline to week 12 visit)","groups":[{"id":"OG000","title":"150 mg od","description":"AZD0837 150 mg od"},{"id":"OG001","title":"300 mg od","description":"AZD0837 300 mg od"},{"id":"OG002","title":"450 mg od","description":"AZD0837 450 mg od"},{"id":"OG003","title":"200 mg bd","description":"AZD0837 200 mg bd"},{"id":"OG004","title":"VKA INR 2-3"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"41"},{"groupId":"OG004","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","lowerLimit":"-1","upperLimit":"24"},{"groupId":"OG001","value":"12.3","lowerLimit":"2","upperLimit":"110"},{"groupId":"OG002","value":"17.4","lowerLimit":"-79","upperLimit":"52"},{"groupId":"OG003","value":"16.4","lowerLimit":"2","upperLimit":"60"}]}]}]},{"type":"SECONDARY","title":"Ecarin Clotting Time (ECT)","description":"Change in Ecarin clotting time (ECT) from baseline to week 12 visit for patients while on study drug (week 12 visit-baseline)","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"sec","timeFrame":"12 weeks according to protocol.(baseline to week 12 visit)","groups":[{"id":"OG000","title":"150 mg od","description":"AZD0837 150 mg od"},{"id":"OG001","title":"300 mg od","description":"AZD0837 300 mg od"},{"id":"OG002","title":"450 mg od","description":"AZD0837 450 mg od"},{"id":"OG003","title":"200 mg bd","description":"AZD0837 200 mg bd"},{"id":"OG004","title":"VKA INR 2-3"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"85"},{"groupId":"OG002","value":"85"},{"groupId":"OG003","value":"98"},{"groupId":"OG004","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.5","lowerLimit":"-1","upperLimit":"86"},{"groupId":"OG001","value":"53.0","lowerLimit":"15","upperLimit":"93"},{"groupId":"OG002","value":"64.0","lowerLimit":"2","upperLimit":"134"},{"groupId":"OG003","value":"73.5","lowerLimit":"-1","upperLimit":"166"}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of AZD0837 (Prodrug)","description":"Assessment made on the week 12 visit","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"nmol/L","timeFrame":"12 weeks after baseline according to protocol","groups":[{"id":"OG000","title":"150 mg od","description":"AZD0837 150 mg od"},{"id":"OG001","title":"300 mg od","description":"AZD0837 300 mg od"},{"id":"OG002","title":"450 mg od","description":"AZD0837 450 mg od"},{"id":"OG003","title":"200 mg bd","description":"AZD0837 200 mg bd"},{"id":"OG004","title":"VKA INR 2-3"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"104"},{"groupId":"OG002","value":"107"},{"groupId":"OG003","value":"112"},{"groupId":"OG004","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"199.8","lowerLimit":"10.0","upperLimit":"2334.0"},{"groupId":"OG001","value":"617.5","lowerLimit":"10.0","upperLimit":"5355.0"},{"groupId":"OG002","value":"564.5","lowerLimit":"10.0","upperLimit":"14720.0"},{"groupId":"OG003","value":"1143.5","lowerLimit":"10.0","upperLimit":"9644.0"}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of AR-H067637XX (Active Metabolite)","description":"Assessment made on the week 12 visit","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"nmol/L","timeFrame":"12 weeks after baseline according to protocol","groups":[{"id":"OG000","title":"150 mg od","description":"AZD0837 150 mg od"},{"id":"OG001","title":"300 mg od","description":"AZD0837 300 mg od"},{"id":"OG002","title":"450 mg od","description":"AZD0837 450 mg od"},{"id":"OG003","title":"200 mg bd","description":"AZD0837 200 mg bd"},{"id":"OG004","title":"VKA INR 2-3"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"104"},{"groupId":"OG002","value":"107"},{"groupId":"OG003","value":"112"},{"groupId":"OG004","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"223.8","lowerLimit":"10.0","upperLimit":"503.9"},{"groupId":"OG001","value":"373.6","lowerLimit":"10.0","upperLimit":"1074.0"},{"groupId":"OG002","value":"454.8","lowerLimit":"10.0","upperLimit":"1490.0"},{"groupId":"OG003","value":"600.8","lowerLimit":"10.0","upperLimit":"1523.0"}]}]}]},{"type":"SECONDARY","title":"Oral Clearance (CL/F) of AR-H067637XX (Active Metabolite) for C3435T Genotype TT","description":"Oral clearance of AR-H067637XX in subgroup of patients with genotype TT for gene polymorphism ABCB1 C3435T","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"L/h","timeFrame":"36 weeks according to protocol","groups":[{"id":"OG000","title":"150 mg od","description":"AZD0837 150 mg od"},{"id":"OG001","title":"300 mg od","description":"AZD0837 300 mg od"},{"id":"OG002","title":"450 mg od","description":"AZD0837 450 mg od"},{"id":"OG003","title":"200 mg bd","description":"AZD0837 200 mg bd"},{"id":"OG004","title":"VKA INR 2-3"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"27"},{"groupId":"OG003","value":"35"},{"groupId":"OG004","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.7","lowerLimit":"22.9","upperLimit":"79.7"},{"groupId":"OG001","value":"42.4","lowerLimit":"13.7","upperLimit":"699"},{"groupId":"OG002","value":"36.3","lowerLimit":"21.4","upperLimit":"62.9"},{"groupId":"OG003","value":"35.6","lowerLimit":"19.7","upperLimit":"67.3"}]}]}]},{"type":"SECONDARY","title":"Oral Clearance (CL/F) of AR-H067637XX (Active Metabolite) for C3435T Genotype TC","description":"Oral clearance of AR-H067637XX in subgroup of patients with genotype TC for gene polymorphism ABCB1 C3435T","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"L/h","timeFrame":"36 weeks according to protocol","groups":[{"id":"OG000","title":"150 mg od","description":"AZD0837 150 mg od"},{"id":"OG001","title":"300 mg od","description":"AZD0837 300 mg od"},{"id":"OG002","title":"450 mg od","description":"AZD0837 450 mg od"},{"id":"OG003","title":"200 mg bd","description":"AZD0837 200 mg bd"},{"id":"OG004","title":"VKA INR 2-3"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"64"},{"groupId":"OG003","value":"66"},{"groupId":"OG004","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.2","lowerLimit":"19.6","upperLimit":"130.5"},{"groupId":"OG001","value":"39.3","lowerLimit":"17.2","upperLimit":"138.6"},{"groupId":"OG002","value":"37.7","lowerLimit":"18","upperLimit":"79.4"},{"groupId":"OG003","value":"40","lowerLimit":"17.4","upperLimit":"96.7"}]}]}]},{"type":"SECONDARY","title":"Oral Clearance (CL/F) of AR-H067637XX (Active Metabolite) for C3435T Genotype CC","description":"Oral clearance of AR-H067637XX in subgroup of patients with genotype CC for gene polymorphism ABCB1 C3435T","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"L/h","timeFrame":"36 weeks according to protocol","groups":[{"id":"OG000","title":"150 mg od","description":"AZD0837 150 mg od"},{"id":"OG001","title":"300 mg od","description":"AZD0837 300 mg od"},{"id":"OG002","title":"450 mg od","description":"AZD0837 450 mg od"},{"id":"OG003","title":"200 mg bd","description":"AZD0837 200 mg bd"},{"id":"OG004","title":"VKA INR 2-3"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"30"},{"groupId":"OG004","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.9","lowerLimit":"23.7","upperLimit":"66"},{"groupId":"OG001","value":"41.1","lowerLimit":"21.8","upperLimit":"62.1"},{"groupId":"OG002","value":"43.4","lowerLimit":"22.8","upperLimit":"78"},{"groupId":"OG003","value":"39.6","lowerLimit":"26.5","upperLimit":"107.1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"AZD0837 150 mg od","seriousNumAffected":12,"seriousNumAtRisk":166,"otherNumAffected":46,"otherNumAtRisk":166},{"id":"EG001","title":"AZD0837 300 mg od","seriousNumAffected":20,"seriousNumAtRisk":152,"otherNumAffected":62,"otherNumAtRisk":152},{"id":"EG002","title":"AZD0837 450 mg od","seriousNumAffected":31,"seriousNumAtRisk":157,"otherNumAffected":46,"otherNumAtRisk":157},{"id":"EG003","title":"AZD0837 200 mg bd","seriousNumAffected":27,"seriousNumAtRisk":161,"otherNumAffected":59,"otherNumAtRisk":161},{"id":"EG004","title":"VKA INR 2-3","seriousNumAffected":50,"seriousNumAtRisk":319,"otherNumAffected":67,"otherNumAtRisk":319}],"seriousEvents":[{"term":"Haemorrhagic Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Cardiac Failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":166},{"groupId":"EG001","numAffected":3,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":1,"numAtRisk":161},{"groupId":"EG004","numAffected":6,"numAtRisk":319}]},{"term":"Atrial Fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":2,"numAtRisk":152},{"groupId":"EG002","numAffected":4,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":4,"numAtRisk":319}]},{"term":"Acute Myocardial Infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Angina Pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":1,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Angina Unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Atrial Flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":1,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":1,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Atrioventricular Block Complete","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":1,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Cardiac Failure Acute","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Cardiac Failure Congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":166},{"groupId":"EG001","numAffected":1,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Coronary Artery Occlusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":1,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Myocardial Infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":1,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Myocardial Ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Sick Sinus Syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":1,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Ventricular Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":2,"numAtRisk":319}]},{"term":"Glaucoma","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Vitreous Haemorrhage","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Abdominal Hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":1,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Abdominal Pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":1,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Anal Ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Gastric Ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Haematemesis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":1,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Inguinal Hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":1,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Periodontal Disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Rectal Haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Asthenia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Chest Pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":1,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Non-Cardiac Chest Pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":1,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Sudden Death","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Chronic Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":1,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Corneal Graft Rejection","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":1,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":2,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Abscess Limb","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":1,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Arthritis Bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Erysipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":1,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Infective Spondylitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Lower Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Postoperative Wound Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":1,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Pyelonephritis Acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":1,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Femoral Neck Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Limb Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":1,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Road Traffic Accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":1,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Tibia Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Haemoglobin Decreased","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":2,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Alanine Aminotransferase Increased","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Blood Glucose Increased","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Diabetes Mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":1,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Gout","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Back Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":1,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Muscular Weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Myositis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":1,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Basal Cell Carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Bladder Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Brain Neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Breast Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":1,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Colon Neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":1,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Prostatic Adenoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Ischaemic Stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":1,"numAtRisk":152},{"groupId":"EG002","numAffected":2,"numAtRisk":157},{"groupId":"EG003","numAffected":2,"numAtRisk":161},{"groupId":"EG004","numAffected":2,"numAtRisk":319}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":1,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Syncope Vasovagal","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":1,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":1,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Transient Ischaemic Attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":1,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Vascular Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Vertebrobasilar Insufficiency","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Pleural Effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":1,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Pulmonary Embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Arterial Stenosis Limb","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Axillary Vein Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Deep Vein Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":1,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":1,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Orthostatic Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":1,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Peripheral Artery Aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"Peripheral Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]},{"term":"Subclavian Vein Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":166},{"groupId":"EG001","numAffected":0,"numAtRisk":152},{"groupId":"EG002","numAffected":0,"numAtRisk":157},{"groupId":"EG003","numAffected":0,"numAtRisk":161},{"groupId":"EG004","numAffected":0,"numAtRisk":319}]}],"otherEvents":[{"term":"DIARRHOEA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":166},{"groupId":"EG001","numAffected":23,"numAtRisk":152},{"groupId":"EG002","numAffected":12,"numAtRisk":157},{"groupId":"EG003","numAffected":17,"numAtRisk":161},{"groupId":"EG004","numAffected":15,"numAtRisk":319}]},{"term":"NAUSEA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":166},{"groupId":"EG001","numAffected":8,"numAtRisk":152},{"groupId":"EG002","numAffected":8,"numAtRisk":157},{"groupId":"EG003","numAffected":9,"numAtRisk":161},{"groupId":"EG004","numAffected":15,"numAtRisk":319}]},{"term":"FLATULENCE","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":166},{"groupId":"EG001","numAffected":11,"numAtRisk":152},{"groupId":"EG002","numAffected":6,"numAtRisk":157},{"groupId":"EG003","numAffected":10,"numAtRisk":161},{"groupId":"EG004","numAffected":1,"numAtRisk":319}]},{"term":"ABDOMINAL PAIN UPPER","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":166},{"groupId":"EG001","numAffected":1,"numAtRisk":152},{"groupId":"EG002","numAffected":8,"numAtRisk":157},{"groupId":"EG003","numAffected":2,"numAtRisk":161},{"groupId":"EG004","numAffected":3,"numAtRisk":319}]},{"term":"NASOPHARYNGITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":166},{"groupId":"EG001","numAffected":10,"numAtRisk":152},{"groupId":"EG002","numAffected":5,"numAtRisk":157},{"groupId":"EG003","numAffected":10,"numAtRisk":161},{"groupId":"EG004","numAffected":20,"numAtRisk":319}]},{"term":"DIZZINESS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":166},{"groupId":"EG001","numAffected":9,"numAtRisk":152},{"groupId":"EG002","numAffected":7,"numAtRisk":157},{"groupId":"EG003","numAffected":11,"numAtRisk":161},{"groupId":"EG004","numAffected":13,"numAtRisk":319}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"pointOfContact":{"title":"Gerard Lynch","organization":"AstraZeneca","email":"aztrial_results_posting@astrazeneca.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"}],"ancestors":[{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000014812","term":"Vitamin K"},{"id":"D000014859","term":"Warfarin"}],"ancestors":[{"id":"D000014815","term":"Vitamins"},{"id":"D000018977","term":"Micronutrients"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000925","term":"Anticoagulants"},{"id":"D000000933","term":"Antifibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000006490","term":"Hemostatics"},{"id":"D000003029","term":"Coagulants"}],"browseLeaves":[{"id":"M17245","name":"Vitamin K","asFound":"Black","relevance":"HIGH"},{"id":"M17248","name":"Vitamins","relevance":"LOW"},{"id":"M16366","name":"Thrombin","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"M17292","name":"Warfarin","asFound":"Third","relevance":"HIGH"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M20699","name":"Micronutrients","relevance":"LOW"},{"id":"M16575","name":"Trace Elements","relevance":"LOW"},{"id":"M3942","name":"Antifibrinolytic Agents","relevance":"LOW"},{"id":"M9266","name":"Hemostatics","relevance":"LOW"},{"id":"M5949","name":"Coagulants","relevance":"LOW"},{"id":"T481","name":"Vitamin K","asFound":"Black","relevance":"HIGH"},{"id":"T450","name":"Menaquinone","relevance":"LOW"},{"id":"T449","name":"Menadione","relevance":"LOW"},{"id":"T452","name":"Naphthoquinone","relevance":"LOW"},{"id":"T458","name":"Phylloquinone","relevance":"LOW"}],"browseBranches":[{"abbrev":"Micro","name":"Micronutrients"},{"abbrev":"Coag","name":"Coagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"Vi","name":"Vitamins"}]}},"hasResults":true}